ESSA Pharma Inc..
EPIX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
ESSA Pharma Inc. is a pharmaceutical company focused on developing novel therapies for prostate cancer. Their primary focus is on small molecule drugs that target the N-terminal domain of the androgen receptor (AR). Their lead product candidate is EPI-7386, an androgen receptor inhibitor. The compan...Show More
Better Health for All
-10
ESSA Pharma's lead product candidate, masofaniten (EPI-7386), showed mixed results. Updated Phase 1/2 clinical data from July 2025 indicated improved PSA levels in patients with metastatic castration-resistant prostate cancer, with 88% achieving PSA90.
1
However, a Phase 2 combination study of masofaniten with enzalutamide was discontinued in October 2024 due to a low likelihood of meeting its primary endpoint, with interim results showing a PSA90 response rate of 64% for the combination versus 73% for enzalutamide monotherapy.
2
The combination therapy was well-tolerated with no new safety signals observed, and no dose-limiting toxicities were reported in the Phase 1/2 study.
3
Research and development expenditures decreased to $3.5 million in Q2 2025 from $6.2 million in Q2 2024, primarily due to the discontinuation of clinical trials.
4
For the full fiscal year 2024, R&D expenditures were $21.2 million, compared to $21.3 million in FY2023.
5
The company received FDA Fast Track Designation for masofaniten in September 2020.
6
Fair Money & Economic Opportunity
0
No evidence available to assess ESSA Pharma Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
10
The CEO's total compensation for Q1 2025 was US$4.1 million.
1
When compared to the average U.S. worker pay of $65,470 in 2023,
2
this results in a CEO to median employee pay ratio of approximately 62.6:1.
3
This ratio falls within the 60-80:1 range.
Fair Trade & Ethical Sourcing
0
The provided articles, primarily ESSA Pharma Inc.'s Form 20-F annual reports from 2016 and 2018, focus on the company's financial performance, clinical development of drug candidates, and associated risks.
1
These documents explicitly state that no quantitative data or specific information related to fair trade, ethical sourcing, or supply chain metrics is provided.
2
Other articles indicate that data extraction was throttled, preventing retrieval of relevant content.
3
Consequently, there is no evidence to assess EPIX.US against any of the Fair Trade & Ethical Sourcing KPIs.
Honest & Fair Business
-50
ESSA Pharma Inc. has a formal whistleblower policy for accounting matters, established in January 2019.
1
This policy allows confidential or anonymous submissions to the CEO or Audit Committee Chair and explicitly commits to non-retaliation.
2
However, there is no evidence of independent investigation processes, training frequency, or program effectiveness metrics.
3
The company also has a Code of Business Conduct and Ethics, which includes provisions for compliance with laws and regulations, fair dealing, and protection of company assets, implying an anti-corruption stance.
4
However, the policy lacks specific guidance on international operations or high-risk markets, and there is no information on training frequency or effectiveness.
5
Kind to Animals
0
The company conducted in vitro and in vivo animal studies to assess the effectiveness of its approach.
1
No information is provided regarding any formal animal testing policy, the volume of animals used, or any other animal welfare-related practices or certifications.
2
No War, No Weapons
0
No evidence available to assess ESSA Pharma Inc. on No War, No Weapons.
Planet-Friendly Business
0
Sustainability data for EPIX.US is currently unavailable.
1
The provided articles do not contain specific, quantitative information regarding environmental performance, targets, or initiatives. While the Corporate Governance and Nomination Committee Charter mentions responsibility for ESG oversight, no details on actual environmental impact, compliance, or specific programs are provided.
2
One article notes a third-party assessment of 'weaknesses in Sustainable Use of Water' but does not provide the underlying quantitative data required for scoring.
3
Respect for Cultures & Communities
0
No evidence available to assess ESSA Pharma Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
ESSA Pharma Inc. states it uses SSL protocol for encryption, which aligns with standard industry practices.
1
The company reports no documented incidents of unauthorized data use.
2
Users can control cookies through browser settings, representing a typical level of user data control.
3
The company states that data is retained only as necessary, with defined retention periods, which is a standard data minimization practice.
4
Furthermore, ESSA Pharma Inc. indicates compliance with GDPR (Articles 13-14) and other applicable laws, reflecting basic regulatory compliance.
5
For all other KPIs, no specific, quantifiable evidence was found in the provided articles.
Zero Waste & Sustainable Products
0
No evidence available to assess ESSA Pharma Inc. on Zero Waste & Sustainable Products.